Rimonabant hydrochlorideCB1 receptor inverse agonist CAS# 158681-13-1 |
- AM630
Catalog No.:BCC1353
CAS No.:164178-33-0
- Nepicastat
Catalog No.:BCC1795
CAS No.:173997-05-2
- JWH 073
Catalog No.:BCC1674
CAS No.:208987-48-8
- CP-945598 HCl
Catalog No.:BCC1082
CAS No.:686347-12-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 158681-13-1 | SDF | Download SDF |
| PubChem ID | 104849 | Appearance | Powder |
| Formula | C22H22Cl4N4O | M.Wt | 500.25 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Rimonabant hydrochloride | ||
| Solubility | DMSO : 33.33 mg/mL (66.63 mM; Need ultrasonic) | ||
| Chemical Name | 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide;hydrochloride | ||
| SMILES | CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl.Cl | ||
| Standard InChIKey | REOYOKXLUFHOBV-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H21Cl3N4O.ClH/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15;/h5-10,13H,2-4,11-12H2,1H3,(H,27,30);1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent and selective cannabinoid CB1 receptor antagonist (Ki = 1.98 nM). Also acts as an inverse agonist reversing adenylyl cyclase inhibition by WIN 55,212-2 (IC50 = 48 nM). Displays no activity at CB2 receptors. Reduces food intake and body weight in orally dosed non-obese Wistar rats. |
Rimonabant hydrochloride Dilution Calculator
Rimonabant hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.999 mL | 9.995 mL | 19.99 mL | 39.98 mL | 49.975 mL |
| 5 mM | 0.3998 mL | 1.999 mL | 3.998 mL | 7.996 mL | 9.995 mL |
| 10 mM | 0.1999 mL | 0.9995 mL | 1.999 mL | 3.998 mL | 4.9975 mL |
| 50 mM | 0.04 mL | 0.1999 mL | 0.3998 mL | 0.7996 mL | 0.9995 mL |
| 100 mM | 0.02 mL | 0.1 mL | 0.1999 mL | 0.3998 mL | 0.4998 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Rimonabant, also known as SR141716, was the first selective central cannabinoid (CB1) receptor inverse agonist (Ki = 1.8 nM) to be developed as an appetite suppressant, anti-obesity drug. Rimonabant is widely used as a tool to investigate CB receptor properties and the mechanisms by which CB agonists exert their pharmacological effects. In rodent models and clinical trials, rimonabant effectively induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios.
- Ombuin 3-glucoside
Catalog No.:BCN4055
CAS No.:158642-42-3
- Eclalbasaponin I
Catalog No.:BCN8244
CAS No.:158511-59-2
- Cnidioside B methyl ester
Catalog No.:BCN1707
CAS No.:158500-59-5
- Catalpalactone
Catalog No.:BCN1708
CAS No.:1585-68-8
- ω-Agatoxin TK
Catalog No.:BCC7489
CAS No.:158484-42-5
- BMS-983970
Catalog No.:BCC5509
CAS No.:1584713-87-0
- PSI
Catalog No.:BCC1124
CAS No.:158442-41-2
- Demethyl calyciphylline A
Catalog No.:BCN7040
CAS No.:1584236-34-9
- Pyraclonil
Catalog No.:BCC8073
CAS No.:158353-15-2
- Methyl 3-(4-methoxyphenyl)propanoate
Catalog No.:BCN4051
CAS No.:15823-04-8
- Naringenin-7-O-glucuronide
Catalog No.:BCC8215
CAS No.:158196-34-0
- Fmoc-Ser(HPO3Bzl)-OH
Catalog No.:BCC3543
CAS No.:158171-14-3
- Dihydrexidine hydrochloride
Catalog No.:BCC5681
CAS No.:158704-02-0
- 2-Naphthyl N-benzoylphenylalaninate
Catalog No.:BCC8583
CAS No.:15873-25-3
- Aescin IIA
Catalog No.:BCN6551
CAS No.:158732-55-9
- Salvianolic acid F
Catalog No.:BCN2924
CAS No.:158732-59-3
- Escin IIB
Catalog No.:BCN8127
CAS No.:158800-83-0
- GR 159897
Catalog No.:BCC7001
CAS No.:158848-32-9
- 3-O-(2'E ,4'Z-decadienoyl)-20-O-acetylingenol
Catalog No.:BCN1550
CAS No.:158850-76-1
- Boc-ß-HoAla-OH
Catalog No.:BCC3224
CAS No.:158851-30-0
- 3Alaph-Tigloyloxypterokaurene L3
Catalog No.:BCN6787
CAS No.:1588516-87-3
- ent-17-Hydroxykaura-9(11),15-dien-19-oic acid
Catalog No.:BCN6788
CAS No.:1588516-88-4
- BET-BAY 002
Catalog No.:BCC5510
CAS No.:1588521-78-1
- GR 231118
Catalog No.:BCC7085
CAS No.:158859-98-4
Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.[Pubmed:16234873]
Drugs Today (Barc). 2005 Aug;41(8):499-508.
Rimonabant hydrochloride, the first drug in a new class of selective cannabinoid type 1 (CB1) receptor antagonists, is showing promise in clinical trials for the treatment of obesity and related metabolic risk factors, in addition to tobacco dependence. Results of phase III clinical trials comparing rimonabant with placebo found that overweight or obese patients, with or without untreated dyslipidemia or type 2 diabetes, lost significant body weight when treated with rimonabant 20 mg for a year. The weight loss was accompanied by a decrease in waist circumference, demonstrating a significant reduction in abdominal obesity, which is an independent marker for cardiovascular disease. Significant improvements were also observed in the lipid profile, with an increase in high-density lipoprotein (HDL) cholesterol and a decrease in triglyceride levels. Improvements in glucose tolerance and insulin levels were also found. Moreover, the number of patients diagnosed with the metabolic syndrome at baseline was significantly reduced. These beneficial effects of rimonabant 20 mg were maintained after 2 years of chronic treatment. Other phase III trials have shown that rimonabant helps people to quit smoking without significant post-cessation weight gain. Rimonabant has a favorable safety profile and is generally well tolerated. Rimonabant is proving to be a very promising approach for managing two major and preventable risk factors for cardiovascular disease. This review summarizes the available evidence on the clinical efficacy and safety of rimonabant as a potential therapy for obesity and smoking cessation.
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.[Pubmed:17882151]
Kidney Int. 2007 Dec;72(11):1345-57.
Obesity is a major risk factor in the development of chronic renal failure. Rimonabant, a cannabinoid CB1 receptor antagonist, improves body weight and metabolic disorders; however, its effect on mortality and chronic renal failure associated with obesity is unknown. Obese Zucker rats received either rimonabant or vehicle for 12 months and were compared to a pair-fed but untreated group of obese rats. Mortality in the obese rats was significantly reduced by rimonabant along with a sustained decrease in body weight, transient reduction in food intake, and an increase in plasma adiponectin. This was associated with significant reduction in plasma total cholesterol, low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio, triglycerides, glucose, norepinephrine, plasminogen activator inhibitor 1, and preservation of pancreatic weight and beta-cell mass index. The cannabinoid antagonist attenuated the increase in proteinuria, urinary N-acetylglucosaminidase excretion, plasma creatinine, and urea nitrogen levels while improving creatinine clearance. Renal hypertrophy along with glomerular and tubulointerstitial lesions were reduced by rimonabant. Although the drug did not modify hemodynamics, it normalized the pressor response to angiotensin II. Our study suggests that in a rat model of chronic renal failure due to obesity, rimonabant preserves renal function and increases survival.
Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.[Pubmed:9718088]
Life Sci. 1998;63(8):PL113-7.
The effect of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight was assessed in adult, non-obese Wistar rats. The daily administration of SR 141716 (2.5 and 10 mg/kg; i.p.) reduced dose-dependently both food intake and body weight. Tolerance to the anorectic effect developed within 5 days; in contrast, body weight in SR 141716-treated rats remained markedly below that of vehicle-treated rats throughout the entire treatment period (14 days). The results suggest that brain cannabinoid receptors are involved in the regulation of appetite and body weight.
Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.[Pubmed:7776817]
Life Sci. 1995;56(23-24):1941-7.
SR141716A is a selective, potent and orally active antagonist of the brain cannabinoid receptor with a long duration of action. This compound shows high affinity for the central cannabinoid receptor (Ki = 2 nM), displays low affinity for the peripheral cannabinoid receptor (Ki > 1000 nM). In vitro, SR141716A antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and dopamine-stimulated adenylyl cyclase activities in rat brain membranes. After oral administration SR141716A totally inhibited the ex vivo [3H]-CP55,940 binding to cerebral membranes with a ED50 value of 3.5 mg/kg. Furthermore SR141716A antagonizes the classical pharmacological responses elicited by cannabinoid receptor agonists. In addition, SR141716A reverses the inhibitory effect of WIN55212-2 on isoniazid-induced elevation of cGMP in rat cerebellum. This compound will provide a powerful tool for studying the in vivo functions of the anandamide/cannabinoid system.
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.[Pubmed:8070571]
FEBS Lett. 1994 Aug 22;350(2-3):240-4.
SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor. This compound displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor. In vitro, SR141716A antagonises the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes. After intraperitoneal or oral administration SR141716A antagonises classical pharmacological and behavioural effects of cannabinoid receptor agonists. This compound should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.
